Atezolizumab

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4787 publications

DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial.

DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial.

Journal: ESMO gastrointestinal oncology

Published: September 03, 2026

Transient pancreatic enlargement with peripancreatic inflammatory changes two days before clinical presentation and diagnosis of atezolizumab-related fulminant type 1 diabetes mellitus followed by pancreatic atrophy: a case report with review of literature.

Transient pancreatic enlargement with peripancreatic inflammatory changes two days before clinical presentation and diagnosis of atezolizumab-related fulminant type 1 diabetes mellitus followed by pancreatic atrophy: a case report with review of literature.

Journal: Endocrine journal

Published: September 02, 2026

FDA approves test for molecular residual disease monitoring in patients with solid tumors: A test enables the identification of patients who are positive for ctDNA and can benefit from adjuvant atezolizumab after cystectomy.

FDA approves test for molecular residual disease monitoring in patients with solid tumors: A test enables the identification of patients who are positive for ctDNA and can benefit from adjuvant atezolizumab after cystectomy.

Journal: Cancer

Published: September 01, 2026

Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States.

Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States.

Journal: Human vaccines & immunotherapeutics

Published: August 22, 2026

Encephalitis, High-Grade Atrioventricular Block, Acute Kidney Injury, and Hepatitis Following Atezolizumab Therapy: A Complex Case of Sequential Multiorgan Immune Checkpoint Inhibitor-Related Adverse Events.

Encephalitis, High-Grade Atrioventricular Block, Acute Kidney Injury, and Hepatitis Following Atezolizumab Therapy: A Complex Case of Sequential Multiorgan Immune Checkpoint Inhibitor-Related Adverse Events.

Journal: Cureus

Published: August 20, 2026

A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment.

A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment.

Journal: Internal medicine (Tokyo, Japan)

Published: August 19, 2026

First-line systemic treatment for people with extensive-stage small cell lung cancer: a network meta-analysis.

First-line systemic treatment for people with extensive-stage small cell lung cancer: a network meta-analysis.

Journal: The Cochrane database of systematic reviews

Published: August 11, 2026

Decoding Primary Refractoriness to Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma: The Myeloid Frontier.

Decoding Primary Refractoriness to Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma: The Myeloid Frontier.

Journal: Journal of hepatology

Published: August 04, 2026

Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade.

Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade.

Journal: Journal for immunotherapy of cancer

Published: July 31, 2026

COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer.

COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 29, 2026

INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol.

INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol.

Journal: BJU international

Published: July 28, 2026

SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.

SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 27, 2026

Showing 1-12 of 4,787

Last Updated: 09/26/2026